Candel Therapeutics, Inc.
Candel Therapeutics, Inc. (CADL): 8 pipeline candidates · ~33 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
32.6 months
D/E 0.46 · 0% dilution
Lead: Phase 3
8 candidates
N/A
1 buy · 0 sells (180d)
A transparent, data-derived signal for Candel Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$595.0M
Cash
$195.3M
Quarterly Burn
$18.0M
Runway
32.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| aglatimagene besadenovec | Phase 2 |
| aglatimagene besadenovec + valacyclovir | Phase 2 |
| Alpha-201 Macro1 | Preclinical |
| CAN-2409 | Phase 3 |
| CAN-3110 | Phase 1 |
| enLIGHTEN™ Discovery Platform (platform-level entry) | Preclinical |
| linoserpaturev | Phase 1 |
| Unnamed enLIGHTEN™ candidate encoding IL-12 and IL-15 | Preclinical |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
112
Total value held
$194.8M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 10,987,017 | $53.8M |
| rtw investments, lp | 6,422,018 | $31.5M |
| vanguard capital management llc | 4,925,514 | $24.1M |
| acorn capital advisors, llc | 3,497,948 | $17.2M |
| blackrock, inc. | 3,109,042 | $15.2M |
| millennium management llc | 1,060,086 | $5.2M |
| geode capital management, llc | 1,035,435 | $5.1M |
| halter ferguson financial inc. | 904,051 | $4.4M |
| state street corp | 818,558 | $4.0M |
| heights capital management, inc | 775,000 | $3.8M |
Showing top 10 of 112 institutional holders of Candel Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Candel Therapeutics, Inc.'s pipeline?
Candel Therapeutics, Inc. (CADL) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Candel Therapeutics, Inc.'s lead drug candidate?
Candel Therapeutics, Inc.'s most advanced tracked candidate is aglatimagene besadenovec (Phase 2) for Prostate Cancer Patients Treated by Radiotherapy.
What is Candel Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Candel Therapeutics, Inc. has approximately 32.6 months of cash runway.
What is Candel Therapeutics, Inc.'s market capitalization?
Candel Therapeutics, Inc.'s market capitalization is approximately $595.0M.
Who is the CEO of Candel Therapeutics, Inc.?
Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. is the chief executive officer of Candel Therapeutics, Inc. (CADL).
Get the full picture on Candel Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.